Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:NRSNNASDAQ:OVIDNASDAQ:QTTBNASDAQ:TZAC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNRSNNeuroSense Therapeutics$1.53+2.0%$1.13$0.51▼$1.65$21.05M1.36255,027 shs140,644 shsOVIDOvid Therapeutics$0.28-6.9%$0.30$0.24▼$3.31$19.91M0.27480,525 shs789,971 shsQTTBQ32 Bio$1.75-7.4%$1.72$1.38▼$53.79$21.35M-0.02197,617 shs74,788 shsTZACTenzing Acquisition$0.97+8.9%$9.02$8.33▼$15.10$4.97M0.0146,767 shs648,440 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNRSNNeuroSense Therapeutics+2.00%+0.66%+56.12%+38.15%+37.84%OVIDOvid Therapeutics-6.95%-1.86%-14.40%-47.17%-90.67%QTTBQ32 Bio-7.41%+8.02%+9.37%-22.91%-93.75%TZACTenzing Acquisition-20.45%-15.14%+1.60%-38.13%-33.51%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationNRSNNeuroSense Therapeutics2.0353 of 5 stars3.53.00.00.01.91.70.0OVIDOvid Therapeutics3.9729 of 5 stars3.52.00.04.61.42.50.6QTTBQ32 Bio2.3744 of 5 stars3.12.00.00.02.71.71.3TZACTenzing AcquisitionN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceNRSNNeuroSense Therapeutics 3.00Buy$14.00815.03% UpsideOVIDOvid Therapeutics 3.00Buy$2.78894.05% UpsideQTTBQ32 Bio 2.25Hold$24.711,312.24% UpsideTZACTenzing Acquisition 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest TZAC, NRSN, OVID, and QTTB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2025OVIDOvid TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$2.00 ➝ $1.505/12/2025NRSNNeuroSense TherapeuticsD Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/12/2025NRSNNeuroSense TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$14.004/24/2025OVIDOvid TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy3/24/2025OVIDOvid TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$5.00 ➝ $4.003/12/2025OVIDOvid TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$4.00 ➝ $3.003/12/2025QTTBQ32 BioWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$16.00 ➝ $15.00(Data available from 5/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookNRSNNeuroSense TherapeuticsN/AN/AN/AN/A($0.14) per shareN/AOVIDOvid Therapeutics$548K36.33N/AN/A$1.24 per share0.23QTTBQ32 Bio-$6.65M-3.21N/AN/A$22.47 per share0.08TZACTenzing AcquisitionN/AN/A$0.01 per share143.10$0.98 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateNRSNNeuroSense Therapeutics-$11.28M-$0.54N/A∞N/AN/AN/A-590.79%6/24/2025 (Estimated)OVIDOvid Therapeutics-$52.34M-$0.35N/AN/AN/A-5,142.56%-39.24%-26.19%8/12/2025 (Estimated)QTTBQ32 Bio-$112.96M-$4.94N/AN/AN/AN/A-146.18%-54.49%8/14/2025 (Estimated)TZACTenzing Acquisition$620KN/A0.00∞N/AN/A-13.32%-1.36%N/ALatest TZAC, NRSN, OVID, and QTTB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/24/2025Q1 2025NRSNNeuroSense Therapeutics-$0.13N/AN/AN/AN/AN/A5/13/2025Q1 2025OVIDOvid Therapeutics-$0.14-$0.14N/A-$0.14$0.03 million$0.13 million5/8/2025Q1 2025QTTBQ32 Bio-$1.23-$0.90+$0.33-$0.90N/AN/A4/7/2025Q4 2024NRSNNeuroSense Therapeutics-$0.12-$0.06+$0.06-$0.06N/AN/A3/11/2025Q4 2024OVIDOvid Therapeutics-$0.16-$0.13+$0.03-$0.13$0.19 million$0.08 million3/11/2025Q4 2024QTTBQ32 Bio-$1.25-$1.16+$0.09-$1.16N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthNRSNNeuroSense TherapeuticsN/AN/AN/AN/AN/AOVIDOvid TherapeuticsN/AN/AN/AN/AN/AQTTBQ32 BioN/AN/AN/AN/AN/ATZACTenzing AcquisitionN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioNRSNNeuroSense TherapeuticsN/A0.21N/AOVIDOvid Therapeutics0.185.665.66QTTBQ32 Bio0.616.536.53TZACTenzing Acquisition0.280.050.05Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipNRSNNeuroSense Therapeutics1.04%OVIDOvid Therapeutics72.24%QTTBQ32 Bio31.32%TZACTenzing Acquisition60.89%Insider OwnershipCompanyInsider OwnershipNRSNNeuroSense Therapeutics27.40%OVIDOvid Therapeutics13.10%QTTBQ32 Bio40.00%TZACTenzing Acquisition37.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableNRSNNeuroSense Therapeutics1013.67 million9.92 millionNot OptionableOVIDOvid Therapeutics6071.11 million61.57 millionOptionableQTTBQ32 Bio3912.20 million10.22 millionN/ATZACTenzing AcquisitionN/A5.12 millionN/ANot OptionableTZAC, NRSN, OVID, and QTTB HeadlinesRecent News About These CompaniesFrom the Archives, 1953: Hillary and Norgay reach the top of the worldJune 8, 2023 | smh.com.auNYC Street in Queens to be Co-named After Tenzing Norgay SherpaApril 21, 2023 | patch.comTenzing Acquisition Corp. NewsOctober 15, 2022 | thestreet.comA 'Gift to the Queen': The First Ever Successful Summit of Mount EverestSeptember 22, 2022 | thewire.inTenzing Norgay Trainor Biography & MoviesSeptember 14, 2022 | tribute.caReviva Pharmaceuticals Holdings, Inc. Common Stock (RVPH)August 12, 2021 | nasdaq.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsTop 4 ETFs for China Exposure After Tariff Relief By Nathan Reiff | May 17, 2025View Top 4 ETFs for China Exposure After Tariff Relief These ETFs Provide Easy Exposure to Growing International MarketsBy Nathan Reiff | May 24, 2025View These ETFs Provide Easy Exposure to Growing International MarketsBuild a Complete Bond Portfolio With These 4 ETFsBy Nathan Reiff | May 17, 2025View Build a Complete Bond Portfolio With These 4 ETFs3 AI ETFs Tapping Into the Heart of the AI RevolutionBy Chris Markoch | May 14, 2025View 3 AI ETFs Tapping Into the Heart of the AI RevolutionTZAC, NRSN, OVID, and QTTB Company DescriptionsNeuroSense Therapeutics NASDAQ:NRSN$1.53 +0.03 (+2.00%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$1.54 +0.01 (+0.65%) As of 05/30/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.Ovid Therapeutics NASDAQ:OVID$0.28 -0.02 (-6.95%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$0.29 +0.01 (+3.57%) As of 05/30/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.Q32 Bio NASDAQ:QTTB$1.75 -0.14 (-7.41%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$1.78 +0.03 (+1.66%) As of 05/30/2025 04:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.Tenzing Acquisition NASDAQ:TZACTenzing Acquisition Corp. does not have significant operations. It intends to acquire, engage in a share exchange, share reconstruction and amalgamation with, purchase all or substantially all of the assets of, enter into contractual arrangements with, or engage in any other similar business combination with one or more businesses or entities primarily operates in India. The company was founded in 2018 and is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/26 - 05/30 Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell Ackman Takes a Swing at Amazon — Should You? Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Intel’s Turnaround May Be the Best Bet No One’s Watching Nike’s Amazon Expansion Could Signal a Turnaround in 2025 ASML Stock Might Be the Safest Chip Play at This Price Archer Aviation Stock Steadies After Short-Seller Report Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
